Navigation Links
Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
Date:7/6/2012

KALAMAZOO, Mich., July 6, 2012 /PRNewswire/ -- Stryker has voluntarily recalled its Rejuvenate and ABG II modular-neck stems.

"While modular-neck stems provide surgeons with an option to correct certain aspects of a patient's anatomy and hip biomechanics, given the potential risks associated with fretting and corrosion at the modular neck junction, Stryker Orthopaedics decided to take this voluntary action," said Stuart Simpson, Vice President and General Manager, Hip Reconstruction.

Stryker Orthopaedics' decision to voluntarily remove Rejuvenate and ABG II modular-neck stems and terminate global distribution of these products comes after continued post-market surveillance. The post-market surveillance data may be predictive of a trend. "Following this action, we will work with the medical community to better understand this matter as we continue to evaluate the data," said Simpson.

Stryker has notified healthcare professionals and regulatory bodies of this voluntary recall.   Patients who received a Rejuvenate Modular or ABG II modular-neck stem are encouraged to contact their surgeon.  Patients uncertain if they have one of these products implanted should contact their surgeon or consult their medical records. 

A dedicated patient call center can be reached at 1-888-317-0200 and additional information can be found at www.AboutStryker.com/ModularNeckStems.

About Stryker Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives. For more information about Stryker, please visit www.stryker.com.


'/>"/>
SOURCE Stryker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
2. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
3. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
6. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
7. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
8. Sensitech Inc. Products Receive Regulatory Compliance Approval from IATA
9. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
10. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
11. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
(Date:3/29/2017)...  Maxor National Pharmacy Services, LLC ("Maxor"), a leading ... Leah Bailey as General Counsel.  Bailey will serve ... With more than 13 years of experience ... on health care, Bailey joins the Maxor team coming ... advised the PBM, Specialty, and Mail Order business areas ...
(Date:3/29/2017)... , March 29, 2017 Varian Medical Systems ... report results for the second quarter of fiscal year 2017 ... 2017.  The news release will be followed by a teleconference ... news release and a link to the conference call webcast ... .  To access the teleconference call and replay: ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash Association, ... enlisted New York City-based sports and entertainment marketing firm Leverage Agency as its ... for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, naming ...
(Date:3/29/2017)... ... ... pollen is the main cause of hay fever in the United States, with an estimated ... from May to July each year; with the worst time for sufferers being June and ... ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Youth Futures ... great success and feedback from high school and college students who have participated in ... held July 7-23 and YFI is now accepting applications for enrollment. Visit ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sports Brand ... brace, which retails normally at $29.97; for the remaining days of March, the ... also been reduced to a special price of just $10 (regular retail price $19.97). ...
(Date:3/29/2017)... Louisiana (PRWEB) , ... March 29, 2017 , ... ... in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of ... Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over the counter ...
Breaking Medicine News(10 mins):